Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EIGR

Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

Eiger BioPharmaceuticals logo

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.30
$7.17
52-Week Range
N/A
Volume
137,800 shs
Average Volume
103,866 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Remembering John Harlin, Eiger Legend
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Eiger Biopharmaceuticals Inc (EIGRQ)
Massive Rockfall on the North Face of the Eiger
Eiger BioPharmaceuticals, Inc. (EIGRQ)
72C.SG,0P00015QPW,0 (72C.SG)
See More Headlines

EIGR Stock Analysis - Frequently Asked Questions

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($19.50) EPS for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company had revenue of $3.04 million for the quarter, compared to analysts' expectations of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%.

Shares of Eiger BioPharmaceuticals reverse split on the morning of Monday, January 8th 2024.The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA).

Company Calendar

Last Earnings
11/04/2021
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EIGR
Employees
56
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$96.78 million
Net Margins
-590.80%
Pretax Margin
-590.79%

Debt

Sales & Book Value

Annual Sales
$15.77 million
Price / Cash Flow
N/A
Book Value
$37.68 per share
Price / Book
N/A

Miscellaneous

Free Float
1,419,000
Market Cap
$2.55 million
Optionable
Optionable
Beta
1.83

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:EIGR) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners